Pre-Clinical Testing
Excerpt from the Press Release: BRISBANE, Calif. – October 7, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data demonstrating that the Company’s novel microbiome-derived peptide, SG-3-0020, can upregulate key co-stimulatory and checkpoint molecules on T cells. The data (poster P260)…
Read MorePresentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Excerpt from the Press Release: NEWARK, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced data on its…
Read More-Preclinical findings that demonstrated efficacy in non-small cell lung cancer (NSCLC) driven by RAS or other MAPK-pathway activating mutations will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics -BridgeBio’s SHP2 inhibitor, BBP-398, is part of its growing precision oncology portfolio, which also includes KRAS inhibitors for KRAS cancers, GPX4 inhibitors…
Read More– AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors. – The collective preclinical data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. This…
Read MorePreclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarks XMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing…
Read MoreExcerpt from the Press Release: LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics.…
Read MoreExcerpt from the Press Release: BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children. The South Asian country is turning…
Read More92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average hospital length of stay in patients treated with TRV027 compared to placebo TRV027 is currently being evaluated in a randomized controlled study (NIH ACTIV-4) and a global adaptive…
Read MorePhase 1 clinical trial currently underway in Australia investigating a noninvasive, oral polymer therapy that dramatically improves glucose homeostasis with weight loss in nonclinical models. Excerpt from the Press Release: BALTIMORE & BOSTON–(BUSINESS WIRE)–Glyscend, Inc. delivered an oral presentation highlighting preclinical data from a study of its oral proprietary polymer duodenal exclusion therapy during the…
Read MoreNew preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern including Beta and Delta– Data also demonstrate trivalent VBI-2901 induced robust and consistent levels of immunity against the ancestral COVID-19 strain and a panel of variants including…
Read More